GlassScriptPhysician profile
Christopher M Mjaanes
NPI 1972660306
$5,911.94
in general payments reported to CMS, 2019-2025
21 companies · $4,649 in 2025
The $4,649 reported for 2025 was more than what 83% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $91.30 · 2021: $294 · 2022: $291 · 2023: $298 · 2024: $64.76 · 2025: $4,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,825 · Food and Beverage: $1,123 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,825.00 |
| Food and Beverage | $1,122.65 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $4,483.82 | 2024-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $505.88 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Pfizer INC. | $153.36 | 2021-2025 | |
| Genzyme Corporation | $119.89 | 2021-2025 | |
| Glaxosmithkline, LLC. | $58.26 | 2019-2025 | Nucala |
| Alk-Abello, INC | $56.74 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $55.17 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.64 | 2021 | |
| Csl Behring | $53.51 | 2019-2025 | Andembry |
| Amgen INC. | $47.77 | 2022-2025 | |
| Octapharma USA, INC. | $46.02 | 2019-2021 | |
| Incyte Corporation | $43.47 | 2022-2023 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.64 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Biocryst US Sales Co., LLC | $35.30 | 2022-2025 | Orladeyo |
| Blueprint Medicines Corporation | $35.25 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $32.40 | 2020-2021 | |
| Abbvie INC. | $28.65 | 2021-2022 | |
| Mylan Specialty L.P. | $20.90 | 2019 | |
| Circassia INC. | $14.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.84 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $13.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mjaanes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.